根據最新的財務報表(Form-10K),Xtant Medical Holdings Inc 的總資產為 $0,淨損失為 $0
XTNT 的關鍵財務比率是什麼?
Xtant Medical Holdings Inc 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
Xtant Medical Holdings Inc 的收入按細分市場或地理位置如何劃分?
Xtant Medical Holdings Inc 最大收入來源為 Orthobiologics,在最近的收益報告中收入為 58,605,000。就地區而言,United States 是 Xtant Medical Holdings Inc 的主要市場,收入為 85,862,000。
Xtant Medical Holdings Inc 是否盈利?
無,根據最新的財務報表,Xtant Medical Holdings Inc 的淨損失為 $0
Xtant Medical Holdings Inc 有負債嗎?
無,Xtant Medical Holdings Inc 的負債為 0
Xtant Medical Holdings Inc 的流通股有多少?
Xtant Medical Holdings Inc 的總流通股為 0
關鍵數據
前收市價
$0.338
開盤價
$0.3352
當日範圍
$0.32 - $0.3583
52週區間
$0.3401 - $0.95
交易量
376.1K
平均成交量
120.5K
股息收益率
--
每股盈餘 (TTM)
0.01
市值
$47.7M
什麼是 XTNT?
Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 151 full-time employees. The company went IPO on 2010-06-30. The firm's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The firm has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows.